INFU
InfuSystem Holdings Inc. [INFU] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
INFU Stock Summary
Top 10 Correlated ETFs
INFU
Top 10 Correlated Stocks
INFU
In the News
INFU Financial details
Company Rating
Buy
Market Cap
170.32M
Income
872K
Revenue
125.79M
Book val./share
2.47
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
499
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
228.86
Forward P/E
-
PEG
0.51
P/S
1.7
P/B
4.03
P/C
802
P/FCF
-102.13
Quick Ratio
1.37
Current Ratio
2.08
Debt / Equity
0.56
LT Debt / Equity
0.56
-
-
EPS (TTM)
0.04
EPS next Y
-
EPS next Q
-
EPS this Y
4511.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-9.67%
Revenue last 5Y
9.17%
Revenue Q/Q
-0.43%
EPS Q/Q
-89.6%
-
-
-
-
SMA20
-11.11%
SMA50
-11.11%
SMA100
-11.11%
Inst Own
54.59%
Inst Trans
0.86%
ROA
1%
ROE
2%
ROC
0.04%
Gross Margin
52%
Oper. Margin
3%
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.87-11.44
52W High
-27.09%
52W Low
+14.57%
RSI
35
Rel Volume
0.42
Avg Volume
45.95K
Volume
19.29K
Perf Week
0.75%
Perf Month
-17.66%
Perf Quarter
-18.33%
Perf Half Y
-17.66%
-
-
-
-
Beta
1.269
-
-
Volatility
0.09%, 0.52%
Prev Close
2.95%
Price
8.02
Change
1.58%
INFU Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.11 | 4.84 | 4.99 | 5.32 | 5.98 | |
| Net income per share | 0.07 | 0.86 | 0.07 | 0 | 0.04 | |
| Operating cash flow per share | 0.7 | 1.01 | 0.89 | 0.85 | 0.53 | |
| Free cash flow per share | -0.44 | 0.17 | 0.08 | 0.12 | 0.01 | |
| Cash per share | 0.13 | 0.48 | 0.01 | 0.01 | 0.01 | |
| Book value per share | 1.13 | 2.03 | 2.35 | 2.32 | 2.49 | |
| Tangible book value per share | 0.35 | 1.47 | 1.64 | 1.74 | 1.96 | |
| Share holders equity per share | 1.13 | 2.03 | 2.35 | 2.32 | 2.49 | |
| Interest debt per share | 2.28 | 2.18 | 1.86 | 1.9 | 1.49 | |
| Market cap | 168.31M | 377.61M | 349.45M | 179.23M | 221.6M | |
| Enterprise value | 208.68M | 410.63M | 386.04M | 215.98M | 256.27M | |
| P/E ratio | 123.67 | 21.79 | 246.09 | 9.96K | 254.12 | |
| Price to sales ratio | 2.07 | 3.88 | 3.41 | 1.63 | 1.76 | |
| POCF ratio | 12.13 | 18.62 | 19.08 | 10.23 | 19.74 | |
| PFCF ratio | -19.3 | 112.18 | 210.51 | 73.43 | 2.09K | |
| P/B Ratio | 7.54 | 9.27 | 7.24 | 3.73 | 4.24 | |
| PTB ratio | 7.54 | 9.27 | 7.24 | 3.73 | 4.24 | |
| EV to sales | 2.57 | 4.22 | 3.77 | 1.97 | 2.04 | |
| Enterprise value over EBITDA | 13.23 | 17.99 | 22.37 | 14.5 | 15.44 | |
| EV to operating cash flow | 15.04 | 20.25 | 21.08 | 12.33 | 22.83 | |
| EV to free cash flow | -23.93 | 121.99 | 232.55 | 88.48 | 2.42K | |
| Earnings yield | 0.01 | 0.05 | 0 | 0 | 0 | |
| Free cash flow yield | -0.05 | 0.01 | 0 | 0.01 | 0 | |
| Debt to equity | 1.93 | 1.05 | 0.76 | 0.79 | 0.56 | |
| Debt to assets | 0.54 | 0.44 | 0.38 | 0.38 | 0.28 | |
| Net debt to EBITDA | 2.56 | 1.45 | 2.12 | 2.47 | 2.09 | |
| Current ratio | 0.88 | 1.29 | 1.71 | 1.71 | 1.95 | |
| Interest coverage | 1.85 | 7.03 | 2.05 | 1.18 | 1.88 | |
| Income quality | 10.19 | 1.17 | 12.9 | 973.17 | 12.87 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0.02 | |
| Payout ratio | 0.19 | 0.01 | 0.79 | 75.28 | 4.9 | |
| Sales general and administrative to revenue | 0.36 | 0.36 | 0.41 | 0.42 | 0.36 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.2 | 0.12 | 0.15 | 0.12 | 0.11 | |
| Capex to operating cash flow | -1.63 | -0.83 | -0.91 | -0.86 | -0.99 | |
| Capex to revenue | -0.28 | -0.17 | -0.16 | -0.14 | -0.09 | |
| Capex to depreciation | -1.83 | -1.21 | -1.14 | -1.13 | -0.89 | |
| Stock based compensation to revenue | 0.01 | 0.03 | 0.06 | 0.03 | 0.03 | |
| Graham number | 1.33 | 6.27 | 1.91 | 0.21 | 1.52 | |
| ROIC | 0.04 | 0.23 | 0.04 | 0 | 0.02 | |
| Return on tangible assets | 0.02 | 0.2 | 0.02 | 0 | 0.01 | |
| Graham Net | -2.22 | -1.69 | -1.74 | -1.75 | -1.54 | |
| Working capital | -2.54M | 6.77M | 9.17M | 10.31M | 14.91M | |
| Tangible asset value | 6.87M | 29.58M | 33.63M | 35.86M | 41.15M | |
| Net current asset value | -37.59M | -26.47M | -27.25M | -26.61M | -19.99M | |
| Invested capital | 1.93 | 1.05 | 0.76 | 0.79 | 0.56 | |
| Average receivables | 10.85M | 13.41M | 15.06M | 16.14M | 18.35M | |
| Average payables | 7.53M | 7.37M | 7.32M | 8.1M | 8.18M | |
| Average inventory | 2.58M | 2.95M | 3.47M | 4.38M | 5.61M | |
| Days sales outstanding | 54.43 | 55.17 | 54.92 | 56.02 | 57.54 | |
| Days payables outstanding | 84.89 | 64.05 | 68.02 | 64.31 | 45.92 | |
| Days of inventory on hand | 30.91 | 28.36 | 34.08 | 37.17 | 36.7 | |
| Receivables turnover | 6.71 | 6.62 | 6.65 | 6.51 | 6.34 | |
| Payables turnover | 4.3 | 5.7 | 5.37 | 5.68 | 7.95 | |
| Inventory turnover | 11.81 | 12.87 | 10.71 | 9.82 | 9.94 | |
| ROE | 0.06 | 0.43 | 0.03 | 0 | 0.02 | |
| Capex per share | -1.15 | -0.84 | -0.81 | -0.73 | -0.53 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.39 | 1.46 | 1.51 | 1.51 | 1.5 | |
| Net income per share | 0.01 | -0.02 | 0.02 | 0.03 | 0 | |
| Operating cash flow per share | 0.22 | -0.01 | 0.12 | 0.2 | 0.22 | |
| Free cash flow per share | 0.02 | -0.21 | -0.04 | 0.12 | -0.28 | |
| Cash per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Book value per share | 2.32 | 2.31 | 2.38 | 2.44 | 2.47 | |
| Tangible book value per share | 1.73 | 1.74 | 1.83 | 1.9 | 1.94 | |
| Share holders equity per share | 2.32 | 2.31 | 2.38 | 2.44 | 2.47 | |
| Interest debt per share | 1.85 | 1.94 | 1.93 | 1.75 | 1.4 | |
| Market cap | 179.82M | 161.61M | 201.8M | 203.36M | 223.34M | |
| Enterprise value | 216.58M | 201.42M | 241.59M | 239.53M | 258.01M | |
| P/E ratio | 420.15 | -124.7 | 115.98 | 73.79 | 775.48 | |
| Price to sales ratio | 6.24 | 5.32 | 6.36 | 6.37 | 7.03 | |
| POCF ratio | 39.38 | -1.07K | 82.3 | 47.69 | 47.95 | |
| PFCF ratio | 350.53 | -36.43 | -268.7 | 77.23 | -38.22 | |
| P/B Ratio | 3.75 | 3.35 | 4.04 | 3.95 | 4.27 | |
| PTB ratio | 3.75 | 3.35 | 4.04 | 3.95 | 4.27 | |
| EV to sales | 7.51 | 6.63 | 7.61 | 7.51 | 8.12 | |
| Enterprise value over EBITDA | 161.02 | 65.8 | 55.63 | 50.42 | 58.72 | |
| EV to operating cash flow | 47.43 | -1.33K | 98.53 | 56.17 | 55.39 | |
| EV to free cash flow | 422.18 | -45.41 | -321.69 | 90.97 | -44.16 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | -0.03 | 0 | 0.01 | -0.03 | |
| Debt to equity | 0.79 | 0.83 | 0.8 | 0.71 | 0.56 | |
| Debt to assets | 0.38 | 0.39 | 0.39 | 0.36 | 0.28 | |
| Net debt to EBITDA | 27.33 | 13.01 | 9.16 | 7.61 | 7.89 | |
| Current ratio | 1.71 | 2 | 2.22 | 2.08 | 1.95 | |
| Interest coverage | 2.42 | -0.29 | 2.01 | 3.01 | 2.49 | |
| Income quality | 42.67 | 0.47 | 5.64 | 6.19 | 64.69 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 1.92 | -1.73 | 0.62 | 0.29 | 0 | |
| Sales general and administrative to revenue | 0.4 | 0.4 | 0.38 | 0.37 | 0.36 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.12 | 0.12 | 0.11 | 0.11 | 0.11 | |
| Capex to operating cash flow | -0.89 | 28.38 | -1.31 | -0.38 | -2.25 | |
| Capex to revenue | -0.14 | -0.14 | -0.1 | -0.05 | -0.33 | |
| Capex to depreciation | -1.31 | -1.34 | -1.04 | -0.53 | -3.34 | |
| Stock based compensation to revenue | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | |
| Graham number | 0.52 | 0.9 | 1.06 | 1.34 | 0.43 | |
| ROIC | 0 | 0 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0.01 | 0 | |
| Graham Net | -1.75 | -1.78 | -1.7 | -1.56 | -1.52 | |
| Working capital | 10.31M | 13.99M | 15.76M | 15.44M | 14.91M | |
| Tangible asset value | 35.86M | 36.36M | 38.3M | 40.07M | 41.15M | |
| Net current asset value | -26.61M | -26.08M | -24.17M | -20.88M | -19.99M | |
| Invested capital | 0.79 | 0.83 | 0.8 | 0.71 | 0.56 | |
| Average receivables | 16.49M | 17.57M | 18.57M | 19.16M | 19.64M | |
| Average payables | 7.49M | 7.85M | 6.42M | 6.56M | 7.82M | |
| Average inventory | 4.84M | 5.23M | 5.68M | 5.9M | 6.25M | |
| Days sales outstanding | 52.67 | 54.13 | 53.52 | 54.87 | 56.17 | |
| Days payables outstanding | 58.9 | 44.71 | 32.26 | 43.84 | 47.09 | |
| Days of inventory on hand | 34.04 | 34.25 | 33.58 | 35 | 37.64 | |
| Receivables turnover | 1.71 | 1.66 | 1.68 | 1.64 | 1.6 | |
| Payables turnover | 1.53 | 2.01 | 2.79 | 2.05 | 1.91 | |
| Inventory turnover | 2.64 | 2.63 | 2.68 | 2.57 | 2.39 | |
| ROE | 0 | -0.01 | 0.01 | 0.01 | 0 | |
| Capex per share | -0.2 | -0.21 | -0.15 | -0.08 | -0.5 |
INFU Frequently Asked Questions
What is InfuSystem Holdings Inc. stock symbol ?
InfuSystem Holdings Inc. is a US stock , located in Rochester hills of Mi and trading under the symbol INFU
What is InfuSystem Holdings Inc. stock quote today ?
InfuSystem Holdings Inc. stock price is $8.02 today.
Is InfuSystem Holdings Inc. stock public?
Yes, InfuSystem Holdings Inc. is a publicly traded company.
Company Profile
- Volume Average 45.95K
- Market Capitalization 170.32M
- Employee 499
- CEO Mr. Richard A. DiIorio
- Headquarters Rochester Hills,MI,US
- IPO Date 2007-12-27
-
Website
https://www.infusystem.com 
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
